Nakai K, Yamamoto T, Aiyama H, Takada T, Yoshida F, Kageji T, Kumada H, Isobe T, Endo K, Matsuda M, Tsurubuchi T, Shibata Y, Takano S, Mizumoto M, Tsuboi K, Matsumura A
Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai, Tsukuba, Japan.
Appl Radiat Isot. 2011 Dec;69(12):1790-2. doi: 10.1016/j.apradiso.2011.03.049. Epub 2011 May 5.
Eight patients to received Boron Neuron Capture Therapy (BNCT) were selected from 33 newly diagnosed glioblastoma patients (NCT(+) group). Serial 42 glioblastoma patients (NCT(-) group) were treated without BNCT. The median OS of the NCT(+) group and NCT (-) group were 24.4 months and 14.9 months. In the high risk patients (RPA class V), the median OS of the NCT(+) group tended to be better than that of NCT(-) group. 50% of BNCT patients were RPA class V.
从33例新诊断的胶质母细胞瘤患者中选取8例接受硼中子俘获疗法（BNCT）的患者（NCT(+)组）。另外42例胶质母细胞瘤患者（NCT(-)组）未接受BNCT治疗。NCT(+)组和NCT(-)组的中位总生存期分别为24.4个月和14.9个月。在高危患者（RPA V级）中，NCT(+)组的中位总生存期倾向于优于NCT(-)组。50%的BNCT患者为RPA V级。
